PTC Therapeutics | PTCT - Assets


PTC Therapeutics reported $3.25B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 92.5B 1.92B Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026
Xencor USD 736.85M 138.65M Mar/2026